After the constant long-term growth of Nasdaq Biotech Index, a significant drop was seen in February and March. The index lost 14 % compared to its February peak, which is the worst drop in a year. Rising interest rates and investors’ refocus on 2020 down-beaten industries could be a reason.
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
The Nasdaq Biotech Index lost 14 % since its peak in February 2021
Monthly market moves of selected competitors compared to NASDAQ Biotechnology Index (NBI)
|
Area |
Company |
Ticker |
Price range $ |
Δ Price |
MktCap $m |
Δ MktCap $m |
| IL |
Nektar Therapeutics |
NKTR |
19.51 – 23.74 |
-12% |
3 588 |
-483 |
|
Xencor |
XNCR |
40.81 – 48.33 |
-13% |
2 474 |
-357 |
|
| ADC |
ADC Therapeutics |
ADCT |
22.75 – 29.40 |
-8% |
1 873 |
-167 |
|
Immunogen |
IMGN |
8.04 – 9.07 |
-7% |
1 519 |
1-22 |
|
|
Mersana Therapeutics |
MRSN |
15.31 – 19.78 |
-11% |
1 108 |
-137 |
|
|
Seattle Genetics |
SGEN |
137.51 – 153.71 |
-8% |
25 037 |
-2 209 |
|
| CAR-T |
Allogene Therapeutics |
ALLO |
32.43 – 39.02 |
2% |
4 952 |
83 |
|
Autolus Therapeutics |
AUTL |
5.49 – 6.96 |
-11% |
299 |
-37 |
|
|
Bellicum Pharma |
BLCM |
3.38 – 4.50 |
-14% |
19 |
-3 |
|
|
Mustang Bio |
MBIO |
3.02 – 3.73 |
-6% |
217 |
-14 |
|
| CPI |
Arcus Biosciences |
RCUS |
28.06 – 39.01 |
-20% |
1 823 |
-466 |
|
Immutep |
IMMP |
2.37 – 3.68 |
15% |
151 |
19 |
|
| DC |
Northwest Biotherapeutics |
NWBO |
1.36 – 1.63 |
3% |
1 090 |
29 |
| PARP |
Clovis Oncology |
CLVS |
5.32 – 7.86 |
17% |
620 |
91 |
Nektar Therapeutics
The short interest of Nektar decreased in March by 6% to 19,944,743 on March 15, compared to 21,247,766 on February 26.
Xencor
Xencor announced it will present preclinical data on three XmAb bispecific antibody programs and the IL-12-Fc cytokine program at AACR Annual Meeting, being held virtually April 10-15, 2021.
ADC Therapeutics
ADCT reported net loss of $56 million, or a $0.73 per share, for 4Q and $246 million, $3.77 per share, for the full year 2020, compared to $35 million, or $0.69 per share, and $117 million, or $2.36 per share, for the same quarter and year-end 2019. The company also announced that Overland ADCT BioPharma launched to develop and commercialize select products in greater China and Singapore.
Immunogen
ImmunoGen reported earnings of 16 cents per share for 4Q of 2020 compared with the year-ago earnings of 3 cents. The estimate stood at a loss of 4 cents per share. Revenues came in at $86 million, which also beat the estimates of $51 million. Revenues were up 91.1% year over year, mainly driven by higher license and milestone fees.
Mersana Therapeutics
Mersana announced that it will present data in three poster sessions at the upcoming Virtual 2021 AACR Annual Meeting being held from April 9-14, 2021. The posters will cover results of XMT-1660 (B7-H4), XMT-2056 (STING) and XMT-1592 (NaPi2b).
Seattle Genetics
Seagen announced that MAA for enfortumab vedotin was accepted by the EMA. The MAA requests review of enfortumab vedotin for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received a PD-1 or PD-L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. If approved, enfortumab vedotin would be the first ADC available in the EU for people living with urothelial cancer.
Allogene Therapeutics
The short interest of Allogene decreased in March by 11% to 10,285,342 on March 15, compared to 11,545,470 on February 26.
Autolus Therapeutics
Autolus announced it will expand on existing operations in the UK for commercial supply of AUTO1 resulting in a less capital-intensive commercial infrastructure strategy. Mutual agreement to terminate lease for the manufacturing and office facility at 9950 Medical Center Drive, Rockville, MD, will result in a cash payment to Autolus. Separately, Autolus reported net loss attributable to shareholders was $142 million for full year 2020, compared to $124 million for the same period in 2019.
Bellicum Pharmaceuticals
Bellicum reported net income of $18.8 million and a net loss $8 million for 4Q and full year 2020, respectively, compared to a net loss of $29 million and $113 million for the comparable periods in 2019. The results included a non-cash gain of $31.9 million and $46.1 million related to the change in fair value of the warrant and private placement option liability for 4Q and year 2020, respectively.
Mustang Bio
Mustang announced its financial results for the year ending December 2020. Net loss attributable to common stockholders was $60 million, or $1.14 per share, compared to a net loss attributable to common stockholders of $46.4 million, or $1.29 per share, in 2019.
Arcus Biosciences
The analysts have sharply increased their revenue numbers, with a view that Arcus will make substantially more sales than they'd previously expected. Following the upgrade, the consensus from eight analysts covering Arcus is for revenues of $63m in 2021.
Immutep
mmutep announced a second clinical trial collaboration and supply agreement with subsidiaries of Merck & Co. Immutep will conduct a new Phase 2b clinical trial in 1st line HNSCC patients, as initially described in the ASX announcement dated 28 September 2020.
NorthWest Biotherapeutics
NW Bio announced that development of the initial production capacity of the company's Sawston, UK advanced manufacturing facility has been completed and the facility is now in the final stages of preparation for an application for certification by the UK MHRA.
Clovis Oncology
Clovis soared it announced positive findings from its Phase 3 study for Rubraca. Data from the trial showed Rubraca reached median PFS of 7.4 months, compared to 5.7 months for those who received chemotherapy, among patients with advanced, relapsed ovarian cancer and a specific gene variant, known as a deleterious BRCA mutation.
